Thrombus aspiration for acute myocardial infarction (AMI) does not reduce mortality or other clinical endpoints long term, according to the awaited one-year follow-up results from the Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE) trial. The findings were presented at ESC Congress today.
Barcelona, Spain – Monday 1 September 2014: Thrombus aspiration for acute myocardial infarction (AMI) does not reduce mortality or other clinical endpoints long term, according to the awaited one-year follow-up results from the Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE) trial. The findings were presented at ESC Congress today by Dr Bo Lagerqvist from Sweden.Dr Lagerqvist said:
“The results of the one-year follow-up of the TASTE trial challenge the current practice of blood clot aspiration after a heart attack.”
TASTE was a multicentre, prospective, randomised, controlled open-label trial that enrolled 7 244 patients from Sweden, Denmark and Iceland who had a diagnosis of ST-elevation myocardial infarction (STEMI). Half of the patients were assigned to balloon treatment only (known as percutaneous coronary intervention, or PCI) and the other half had their blood clot aspirated before PCI.As previously reported from the TASTE trial, the death rate when the patients were followed 30 days after treatment was not lower after clot aspiration. Today the investigators report the results after patients have been followed for one year.The results presented today are consistent with the previous report. After one year the death rate was not statistically different between the two treatment groups (5.3% after clot aspiration and 5.6% after PCI alone). Similarly, there was no difference between the two groups regarding other endpoints including the risk of new heart attack, stroke and complications related to the treatment. Even high risk groups such as smokers, patients with diabetes or patients with large clots had similar results with either approach.Dr Lagerqvist said: “Our findings do not support a role for this clot aspiration as a routine additional treatment in heart attacks.”He added:
“Current ESC guidelines on treatment of patients with STEMI recommend that thrombus aspiration should be considered (1) and most opinion leaders advocate its use. Since the TAPAS trial suggested a mortality benefit after one year (2) thrombus aspiration has gained enormous popularity. The therapy is so popular among interventional cardiologists because it intuitively feels beneficial to aspirate the clot that closes the artery.”
Dr Lagerqvist continued:
“The TASTE trial is the first large-scale randomised trial of thrombus aspiration for STEMI to be large enough to reveal meaningful findings on mortality and morbidity. It enrolled more patients than all previous randomised trials of this procedure combined and included a much broader range of patients in order to make the results relevant to everyday clinical practice.”
The study’s unique Registry-Based Randomised Clinical Trial (RRCT) protocol used national registries as on-line platforms for randomisation, case record forms and follow-up, making the trial economically and administratively feasible.Study chair Professor Stefan James (Sweden) said:
“TASTE is the first trial ever to use the registry based trial concept. This concept enabled enrolment of more than 80% of all eligible patients nationwide with complete control of the non-enrolled patients and unlimited duration of follow-up at a very low cost.”
(1) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012;33:2569–2619. doi:10.1093/eurheartj/ehs215(2) Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):557-567. doi: 10.1056/NEJMoa0706416. (full paper available in the press kit)
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2014The ESC Congress is currently the world's largest international congress in cardiovascular medicine. The spotlight of this year's event is “innovation and the heart”. ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved